Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

1. A compound represented by Structural Formula VII or VIII:

wherein

R 1a is selected from hydrogen, halogen, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkyl, —O—(C 1 -C 4 )alkyl, (C 3 -C 12 )carbocyclyl and (C 3 -C 7 )heterocyclyl, wherein each alkyl, carbocyclyl and heterocyclyl is optionally and independently substituted;

R 9a is optionally substituted aryl or optionally substituted heteroaryl;

m′ is 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. A compound represented by

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising:

(a) a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and

(b) a pharmaceutically acceptable carrier.

4. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the cancer is lymphoma.

6. The method of claim 4 , wherein the cancer is cervical cancer.

7. The method of claim 4 , wherein the cancer is mantle cell lymphoma.

8. The method of claim 4 , wherein the cancer is selected from non-Hodgkin lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, erythroleukemia, multiple myeloma, cervical cancer, ovarian cancer, osteosarcoma, prostate cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, lung cancer, glioblastoma, glioma, liver cancer, bile duct cancer, pancreatic cancer, hepatoma, neuroblastoma, testicular cancer, mesothelioma, and fibrosarcoma.

9. The method of claim 8 , wherein the non-Hodgkin lymphoma is selected from histiocytic lymphoma, mantle cell lymphoma, Burkett lymphoma, and diffuse large B-cell lymphoma.

10. The method of claim 4 , wherein the cancer is selected from chronic lymphocytic leukemia, T-cell leukemia, and B-cell leukemia.

11. The compound of claim 1 , wherein R 1a is optionally substituted phenyl.

12. The compound of claim 11 , wherein one or more optional substituents on phenyl are selected from halogen, alkyl, haloalkyl, CN, and —OH.

13. The compound of claim 12 , wherein R 1a is substituted with halogen.

14. The compound of claim 1 , wherein R 9a is substituted with —C(O)(C 0 -C 1 alkylene)NR 11 R 12 ,

wherein R 11 and R 12 are taken together with the nitrogen atom to which they are commonly attached to form an optionally substituted (C 3 -C 7 )heterocyclyl; and is further optionally substituted with 1 or 2 substituents independently selected from halogen, (C 1 -C 4 )alkyl and (C 1 -C 4 )haloalkyl.

15. The compound of claim 14 , wherein R 9a is phenyl or a 6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur;

substituted at the meta or para position relative to its attachment point with —C(O)(C 0 -C 1 alkylene)NR 11 R 12 , wherein R 11 and R 12 are taken together with the nitrogen atom to which they are commonly attached to form an optionally substituted (C 3 -C 7 )heterocyclyl; and further optionally substituted with 1 or 2 substituents independently selected from halogen, (C 1 -C 4 )alkyl and (C 1 -C 4 )haloalkyl.

16. The compound of claim 1 , wherein R 9a is selected from 4-(morpholine-4-carbonyl) phenyl, 4-(3,3-difluoroazetidine-1-carbonyl)phenyl), 4-(4-trifluoromethyl)phenyl, 4-methylsulfonylphenyl, 4-ethylsulfonylphenyl, 4-fluorophenoxy, 4,4-difluorocyclohexyloxy, and 4-fluoropyridyloxy.

17. A pharmaceutical composition comprising a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.